Randomized Trialhigh evidence
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
The New England journal of medicine·September 18, 2025·PMID 40544435
Why it mattersOrforglipron is a nonpeptide oral GLP-1 agonist, offering a potential alternative to injectable GLP-1 therapies. This trial provides robust phase 3 evidence of its efficacy and safety in early diabetes, which may influence oral treatment options and patient adherence.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled